Generic Version

Type: Keyphrase
Name: Generic Version
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Pharmaceutical companies refute Congress' post claiming hike in prices of life-saving drugs

B y Divya RajagopalMUMBAI: A post on the Congress party's website claiming steep hikes in the prices of life-saving medicines, especially cancer drug Glivec, has led to the social media playing it up and also creating confusion.Novartis, which owns the ... [Published Economic Times - 8 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Actavis in Patent Infringement Lawsuit for Purdue's Butrans - Analyst Blog

Purdue has filed a patent infringement lawsuit against Actavis in the U.S. District Court for the District of Delaware in order to prevent Actavis from commercializing its generic version of Butrans prior to the expiration of certain U.S. Patents. With ... [Published Nasdaq - 11 hours ago]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

Par begins shipping generic Exforge tabs

WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths. The tablets are the generic version of Exforge from Novartis and are used to treat hypertension ... [Published Drug Store News - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Sam's Club or Walmart: Which saves you more?

PHOENIX - Sam's Club vs Walmart : same owner, but different prices.At Sam's Club, you'll pay $45 for a yearly membership. At Walmart, you have low prices with no membership.Is it worth the cost or can you get better deals at Walmart?I shopped more than ... [Published ABC15.com - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Alabama Supreme Court upholds decision allowing innovator liability

, the Alabama Supreme Court issued a decision following rehearing in Wyeth, Inc. v. Weeks, 2014 WL 4055813 (Ala. Aug. 15, 2014) (" Weeks II"). The court held that a brand-name drug company may be liable for fraud or misrepresentation to a plaintiff claiming ... [Published Lexology - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Court Report - September 2014 #6

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Cadence Pharmaceuticals Inc. et al. v. InnoPharma Licensing LLC et al.1:14-cv-01225; filed September 24, 2014 in the District Court of Delaware• Plaintiffs:  ... [Published JD Supra - Sep 29 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Actavis confirms generic Butrans patent challenge

Actavis confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market buprenorphine transdermal system, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr.Actavis' ANDA product is a generic ... [Published PharmaBiz - Sep 27 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Par Will Pay $100 Million in Zegerid Patent Infringement Suit

Generics firm Par Pharmaceuticals has agreed to pay Salix Pharmaceuticals $100 million to settle a patent infringement lawsuit over its version of Salix’s heartburn drug Zegerid.The settlement covers Salix, its subsidiary Santarus and curators of the ... [Published FDA News - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Can Valeant's Glaucoma Drug Peak Sales Be Much Lower Than Claimed?

By Uncommon Profit Investor :I was inspired to write this article by SA commenters who work in the eyecare field. They know a lot more than me of course. One said he has extensive ophthalmology experience and the other is an optometrist . Both of them ... [Published BioPortfolio - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 2 reports

Actavis confirms patent challenge for generic Butrans

DUBLIN — Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. The drug is used for the treatment ... [Published Drug Store News - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 2 reports

Dr. Reddy's (RDY) Generic Xopenex Launched in the US

Dr. Reddy's Laboratories Ltd. ( RDY - Analyst Report ) has launched its generic version of Sunovion Pharmaceuticals Inc.’s Xopenex inhalation solution (0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL unit-dose vials) in the U.S. It can be used only with a ... [Published Zacks.com - Sep 25 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 2 reports

VA Pharmacy evacuated during hazmat scare

TAMPA (FOX 13) -Hillsborough County Fire Rescue responded to a hazardous materials incident at the VA Pharmacy in Tampa Wednesday.When crews arrived, the building had been evacuated.They said three employees had been isolated due to coming in contact ... [Published WTVT FOX 13 - Sep 25 2014]

Quotes

..."This information is absolutely false," said Adi Narayan, company secretary at Natco. "The price of Glivec was revised downwards by 93% under DPCO (drug price control order) 2013 and remains unchanged." said Ranjit Shahani, vice chairman and managing director of Novartis India
...setting is perfect," says the blue-eyed blond woman with the British accent as she lies on a canopy bed with a tropical scene in the background. "But then, erectile dysfunction happens again. Plenty of guys have this issue - not just getting an erection, but keeping it. And you only take it when you need it. If ED is stopping what you started, ask your doctor about Viagra."
Dr. Michael Baird, the Chief Science Officer of DDC, and considered the country's foremost expert in DNA and paternity testing, proclaims that "DDC provides the only home paternity test in the US market that is always tested twice, and a serious tool that could change the dynamic of the customer's family forever." Dr. Baird was the first person to testify in a criminal DNA case in the U S , and since 1987, has been involved in more than 300 court cases involving...
...2014 WL 4055813, at *22. The court stated that under the regulatory scheme, Wyeth "authored the label with its warnings, and the generic manufacturers, as required by FDA regulations, copied that label verbatim." Id. at *21. Thus, the court found plaintiff's fraud claim was not the same as "a products-liability claim where privity is needed." Id

More Content

All (603) | News (439) | Reports (0) | Blogs (153) | Audio/Video (0) | Fact Sheets (0) | Press Releases (9)
sort by: Date | Relevance
Dr. Reddy's launches Levalbuterol inhalation so... [Published Individual.com - 4 mins ago]
Pharmaceutical companies refute Congress' post ... [Published Economic Times - 8 hours ago]
Actavis in Patent Infringement Lawsuit for Purd... [Published Nasdaq - 11 hours ago]
Turning Positive On Cumberland Pharmaceuticals ... [Published Seeking Alpha - 15 hours ago]
Viagra ads becoming more explicit [Published Philly.com - Oct 01 2014]
Par begins shipping generic Exforge tabs [Published Drug Store News - Sep 30 2014]
Update from the Finnish courts [Published World Intellectual Property Review - Sep 30 2014]
DNA Diagnostics Center launches new Paternity T... [Published News-Medical.Net - Sep 30 2014]
Alabama Supreme Court upholds decision allowing... [Published Lexology - Sep 30 2014]
Par Pharmaceutical Begins Shipment of Generic E... [Published Scottrade - Sep 30 2014]
Par Pharmaceutical Begins Shipment of Generic E... [Published PR Newswire: General Business - Sep 30 2014]
Trial court denies injunction to BMS against My... [Published PharmaBiz - Sep 30 2014]
Baiyunshan Gets CFDA Approval For Generic Viagra [Published Asian Scientist - Sep 30 2014]
Sam's Club or Walmart: Which saves you more? [Published ABC15.com - Sep 30 2014]
Pharmaceutical companies conspired to keep more... [Published Natural News - Sep 30 2014]
Amag $1 billion deal to buy preterm birth drug ... [Published Pharma Times - Sep 30 2014]
Broader UK experimental use exemption coming in... [Published Mewburn Ellis - Sep 29 2014]
Court Report - September 2014 #6 [Published JD Supra - Sep 29 2014]
INSYS THERAPEUTICS : Receives FDA Orphan Drug D... [Published 4 Traders - Sep 29 2014]
Pricing row hits pharma industry [Published The Hindu - Sep 28 2014]
High cost of cure sparks ethical dilemma [Published Albuquerque Journal - Sep 28 2014]
Meet 5 Top Stocks With Rising Earnings Estim… [Published Investor's Business Daily - Sep 27 2014]
Actavis confirms generic Butrans patent challenge [Published PharmaBiz - Sep 27 2014]
Par Will Pay $100 Million in Zegerid Patent Inf... [Published FDA News - Sep 27 2014]
10 Mistakes To Avoid When Trying To Save Money [Published Investopedia - Sep 27 2014]
New drug era [Published Indian Express - Sep 26 2014]
Can Valeant's Glaucoma Drug Peak Sales Be Much ... [Published BioPortfolio - Sep 26 2014]
Camber launches generic Evista [Published Drug Store News - Sep 26 2014]
Actavis confirms patent challenge for generic B... [Published Drug Store News - Sep 26 2014]
Camber Pharma Launches Generic Evista [Published Pharmacy Times - Sep 26 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Par Pharmaceutical Begins Shipment of Generic E... [Published PR Newswire: General Business - Sep 30 2014]
WOODCLIFF LAKE, N.J., Sept. 30, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge®.  Par received final approval ...
Actavis confirms generic butrans patent challenge [Published PBR - News - Sep 26 2014]
Actavis confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a ...
Dr. Reddy’s Announces the Launch of LEVALBUTERO... [Published EON Science - Sep 24 2014]
HYDERABAD, India--(EON: Enhanced Online News)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic ...
Dr. Reddy’s Announces the Launch of LEVALBUTERO... [Published Business Wire Science: Science News - Sep 24 2014]
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of ...
Dr. Reddy’s Announces the Launch of LEVALBUTERO... [Published Business Wire Health News - Sep 24 2014]
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
FDA Receives Paragraph IV Notice Letter for KUV... [Published GlobeNewswire: Advertising News - Sep 24 2014]
Orion announces amended settlement agreement ov... [Published GlobeNewswire: Advertising News - Sep 22 2014]
Momenta Pharmaceuticals to Webcast Presentation... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
Mylan Wins Motion to Enjoin GlaxoSmithKline fro... [Published Financial Services - Jul 17 2014]
Milan District Court Confirms the Validity of A... [Published Financial Services - Jun 12 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.